Two of the four subsequent publications using this assay in NSCLC have demonstrated an apparent value for this PD- L1 test. In the smaller CHECKMATE 063, a single arm study in squamous NSCLC, 24 % of PD-L1 positive patients (n = 25) and 14 % of negative patients (n = 51) had an ...
For patients with a negative PD-L1 expression of less than 1, there is a consistent lack of benefit observed. He also noted that 80% to 90% of patients have a positive PD-L1 expression, meaning that a potential PD-L1 cutoff of 1 wou...
48,49 Data from phase 3 randomized trials investigating pembrolizumab in the recurrent or metastatic setting (KEYNOTE-048 and KEYNOTE-040) showed considerably increased survival in PD-L1–positive patients,48-50 suggesting that PD-L1 may be a potential biomarker. This association in the neoadjuvant...
The best examples of this testing are in breast cancer, in which estrogen receptor must be expressed in more than 1% of cells, at any intensity, to be considered positive.4 For PD-L1, 3 drug-specific tests are FDA approved as either companion (pembrolizumab) or complementary (atezolizumab ...
At present, the current clinical studies suggest prolonged overall survival for PD-L1-positive patients with IC scores >1% in breast cancer8. However, with the development of clinical trials and the increasingly prominent role of precision medicine, the cutoff value of PD-L1 expression should be ...
a. Receiver Operative Characteristic curves of models for WSI-level prediction among four independent test cohorts;b. True Positive Rate - False Positive Rate curve in internal test cohort;c. comparison of the ICIsNet output between well and poor responses in the internal test cohort;d. comparison...
Citation22 Tumors with low PD-L1 expression may show limited responsiveness to PD-1/PD-L1 inhibitors due to insufficient PD-L1 molecules for engaging immune checkpoint inhibitors.Citation23 In the clinical setting, both the PD-L1 tumor proportion score (TPS) and the PD-L1 combined positive ...
information was not mandatory for PD-1/PD-L1 inhibitor prescription in pretreated patients with NSCLC and because the percentage of positive expression was often not provided and tested with heterogeneous methods; therefore, we were unable to precisely characterize the interplay between PD-L1 status ...
Although the frequency of any preexisting antibody and rheumatoid factor tended to be slightly higher in the strong positive group, no significant differences were observed in antibody frequency. This result may suggest that these antibodies represent independent markers of PD-L1. To our knowledge, ...
A large number of researches show that a tumor microenvironment can protect tumor cells from being damaged by immune cells, expression of PD-1 in lymphocytes infiltrated in the tumor microenvironment is up-regulated, and various primary tumor tissues are PD-L1 positive in immunohistochemical analysis...